Peer-reviewed article
Protecting newborns and infants before birth: Accelerating equitable maternal vaccine introduction in low‐ and middle‐income countries
Annettee Nakimuli, Kate Fay, Michelle J. Groome, Hellen Barsosio, Eve Nakabembe et al. ·
Summary
Written by AI, not yet AICS's view · claude-sonnet-5-5This article argues that vaccinating pregnant women can protect newborns and infants before they are old enough for routine infant immunisation. It points to the maternal tetanus toxoid programme as proof that this approach works. It says new maternal vaccines for RSV, and possibly Group B Streptococcus, could further improve newborn and infant survival, especially in low- and middle-income countries where most infant deaths occur. Only the opening of the article is available, so the full argument about equitable introduction is not covered.
Key points
- Neonatal infections such as pneumonia, sepsis and meningitis cause more than 550,000 newborn deaths globally each year.
- When pregnant women received at least two doses of tetanus toxoid vaccine, global neonatal tetanus deaths fell by 94%.
- New maternal vaccines for RSV, and potentially soon for GBS, could further improve newborn and infant survival.
- Nearly 95% of these infant deaths occur in low- and middle-income countries, where alternative prevention options are most limited.
- RSV is a major cause of viral pneumonia in young children in LMICs and leads to the hospitalisation of 1.4 million infants.
Limitations
The text is only a short extract of the introduction, so it does not show the article's recommendations, methods or evidence on how to introduce maternal vaccines equitably. The country hints in the metadata are not matched by any country named in the extract, and the work appears to be global in scope.
Abstract
Protecting newborns and infants before birth: Accelerating equitable maternal vaccine introduction in low-and middle-income countriesEach year, neonatal infections-including pneumonia, sepsis, and meningitis-cause more than 550 000 newborn deaths globally, many occurring before newborns and infants can benefit from routine infant immunization.1 Maternal immunization offers a powerful and tested solution: protecting infants before birth.The success of the maternal tetanus toxoid (TT) vaccine program bears this out: when pregnant women received at least two doses of TT vaccine, global neonatal tetanus deaths fell by 94%. 2 New maternal vaccines for Respiratory Syncytial Virus (RSV)-and potentially soon for Group B Streptococcus (GBS)-could further improve newborn and infant survival.For women, families, and their obstetricians and midwives, this early window of vulnerability is a critical time.Prevention of infant death is a global priority but is most urgent in low-and middle-income countries (LMICs), where nearly 95% of the deaths occur and where access to alternative prevention strategies is most constrained.RSV is a major cause of viral pneumonia in young children and in LMICs, causing more than 100 00 child deaths every year and the hospitalization of 1.4 million infants aged under Annettee Nakimuli 1